The VASCERN-VASCA working group diagnostic and management pathways for lymphatic malformations.

Alpelisib Interventional radiology Lymphatic malformation Management PIK3CA Patient pathway Sclerotherapy Sirolimus Surgery Treatment algorithm Vascular malformation

Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 01 12 2021
revised: 30 07 2022
accepted: 01 10 2022
pubmed: 13 10 2022
medline: 22 11 2022
entrez: 12 10 2022
Statut: ppublish

Résumé

Lymphatic malformations (LMs) are developmental defects of lymphatic vessels. LMs are histologically benign lesions, however, due to localization, size, and unexpected swelling, they may cause serious complications that threaten vital functions such as compression of the airways. A large swelling of the face or neck may also be disfiguring and thus constitute a psychological strain for patients and their families. LMs are also highly immunologically reactive, and are prone to recurrent infections and inflammation causing pain as well as chronic oozing wounds. The European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN) is dedicated to gathering the best expertise in Europe. There are only few available guidelines on management and follow up of LMs, which commonly focus on very specific situations, such as head and neck LM (Zhou et al., 2011). It is still unclear, what constitutes an indication for treatment of LMs and how to follow up the patients. The Vascular Anomalies Working Group (VASCA-WG) of VASCERN decided to develop a diagnostic and management pathway for the management of LMs with a Nominal Group Technique (NGT), a well-established, structured, multistep, facilitated group meeting technique used to generate consensus statements. The pathway was drawn following 2 face-to-face meetings and multiple web meetings to facilitate discussion, and by mail to avoid the influence of most authoritative members. The VASCA-WG has produced this opinion statement reflecting strategies developed by experts and patient representatives on how to approach patients with lymphatic malformations in a practical manner; we present an algorithmic view of the results of our work.

Identifiants

pubmed: 36223836
pii: S1769-7212(22)00218-X
doi: 10.1016/j.ejmg.2022.104637
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104637

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Nader Ghaffarpour (N)

Department of Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden. Electronic address: nader.ghaffarpour@regionstockholm.se.

Eulalia Baselga (E)

Pediatric Dermatology, Hospital Sant Joan de Deu, Barcelona, Spain.

Laurence M Boon (LM)

Center for Vascular Anomalies, Division of Plastic Surgery, University Clinics Saint-Luc, University of Louvain, Brussels, Belgium; VASCERN VASCA European Reference Centre University of Louvain, Brussels, Belgium.

Andrea Diociaiuti (A)

Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy.

Anne Dompmartin (A)

Department of Dermatology, Université de Caen Basse Normandie, CHU Caen, Caen, France.

Veronika Dvorakova (V)

Paediatric Dermatology, Children's Health Ireland, (Y)Clinical Medicine, Trinity College Dublin, Ireland.

May El Hachem (M)

Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy.

Paolo Gasparella (P)

Department of Paediatric and Adolescent Surgery, Medical University of Graz, Graz, Austria.

Emir Haxhija (E)

Department of Paediatric and Adolescent Surgery, Medical University of Graz, Graz, Austria.

Kristiina Kyrklund (K)

Department of Pediatric Surgery, HUS Rare Disease Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Alan D Irvine (AD)

Paediatric Dermatology, Children's Health Ireland, (Y)Clinical Medicine, Trinity College Dublin, Ireland.

Friedrich G Kapp (FG)

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Jochen Rößler (J)

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Päivi Salminen (P)

Department of Pediatric Surgery, HUS Rare Disease Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Caroline van den Bosch (C)

Hevas, Patient Organisation for Vascular Anomalies, the Netherlands.

Carine van der Vleuten (C)

Department of Dermatology, Radboudumc Expertise Center for Haemangiomas and Congenital Vascular Malformations Nijmegen (Hecovan), Radboud University Medical Center, Nijmegen, the Netherlands.

Leo Schultze Kool (LS)

Department of Radiology, Radboudumc Expertise Center for Haemangiomas and Congenital Vascular Malformations Nijmegen (Hecovan), Radboud University Medical Center, Nijmegen, the Netherlands.

Miikka Vikkula (M)

Center for Vascular Anomalies, Division of Plastic Surgery, University Clinics Saint-Luc, University of Louvain, Brussels, Belgium; VASCERN VASCA European Reference Centre University of Louvain, Brussels, Belgium; Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH